1.Targeted inhibition of osteoclastogenesis reveals the pathogenesis and therapeutics of bone loss under sympathetic neurostress.
Bingdong SUI ; Jin LIU ; Chenxi ZHENG ; Lei DANG ; Ji CHEN ; Yuan CAO ; Kaichao ZHANG ; Lu LIU ; Minyan DANG ; Liqiang ZHANG ; Nan CHEN ; Tao HE ; Kun XUAN ; Fang JIN ; Ge ZHANG ; Yan JIN ; Chenghu HU
International Journal of Oral Science 2022;14(1):39-39
Sympathetic cues via the adrenergic signaling critically regulate bone homeostasis and contribute to neurostress-induced bone loss, but the mechanisms and therapeutics remain incompletely elucidated. Here, we reveal an osteoclastogenesis-centered functionally important osteopenic pathogenesis under sympatho-adrenergic activation with characterized microRNA response and efficient therapeutics. We discovered that osteoclastic miR-21 was tightly regulated by sympatho-adrenergic cues downstream the β2-adrenergic receptor (β2AR) signaling, critically modulated osteoclastogenesis in vivo by inhibiting programmed cell death 4 (Pdcd4), and mediated detrimental effects of both isoproterenol (ISO) and chronic variable stress (CVS) on bone. Intriguingly, without affecting osteoblastic bone formation, bone protection against ISO and CVS was sufficiently achieved by a (D-Asp8)-lipid nanoparticle-mediated targeted inhibition of osteoclastic miR-21 or by clinically relevant drugs to suppress osteoclastogenesis. Collectively, these results unravel a previously underdetermined molecular and functional paradigm that osteoclastogenesis crucially contributes to sympatho-adrenergic regulation of bone and establish multiple targeted therapeutic strategies to counteract osteopenias under stresses.
Adrenergic Agents/pharmacology*
;
Apoptosis Regulatory Proteins/pharmacology*
;
Bone Diseases, Metabolic/metabolism*
;
Humans
;
Liposomes
;
MicroRNAs/genetics*
;
Nanoparticles
;
Osteoclasts
;
Osteogenesis/physiology*
;
RNA-Binding Proteins/pharmacology*
2.Neonatal Maternal Deprivation Followed by Adult Stress Enhances Adrenergic Signaling to Advance Visceral Hypersensitivity.
Wan-Jie DU ; Shufen HU ; Xin LI ; Ping-An ZHANG ; Xinghong JIANG ; Shan-Ping YU ; Guang-Yin XU
Neuroscience Bulletin 2019;35(1):4-14
The pathophysiology of visceral pain in patients with irritable bowel syndrome remains largely unknown. Our previous study showed that neonatal maternal deprivation (NMD) does not induce visceral hypersensitivity at the age of 6 weeks in rats. The aim of this study was to determine whether NMD followed by adult stress at the age of 6 weeks induces visceral pain in rats and to investigate the roles of adrenergic signaling in visceral pain. Here we showed that NMD rats exhibited visceral hypersensitivity 6 h and 24 h after the termination of adult multiple stressors (AMSs). The plasma level of norepinephrine was significantly increased in NMD rats after AMSs. Whole-cell patch-clamp recording showed that the excitability of dorsal root ganglion (DRG) neurons from NMD rats with AMSs was remarkably increased. The expression of β adrenergic receptors at the protein and mRNA levels was markedly higher in NMD rats with AMSs than in rats with NMD alone. Inhibition of β adrenergic receptors with propranolol or butoxamine enhanced the colorectal distention threshold and application of butoxamine also reversed the enhanced hypersensitivity of DRG neurons. Overall, our data demonstrate that AMS induces visceral hypersensitivity in NMD rats, in part due to enhanced NE-β adrenergic signaling in DRGs.
Adrenergic Agents
;
pharmacology
;
Animals
;
Ganglia, Spinal
;
drug effects
;
Hyperalgesia
;
drug therapy
;
physiopathology
;
Hypersensitivity
;
drug therapy
;
Male
;
Maternal Deprivation
;
Neurons
;
drug effects
;
Patch-Clamp Techniques
;
methods
;
Rats, Sprague-Dawley
;
Signal Transduction
;
drug effects
;
Stress, Physiological
;
physiology
;
Visceral Pain
;
chemically induced
;
metabolism
3.Renal sympathetic nerve activation via α₂-adrenergic receptors in chronic kidney disease progression
Hee Seong JANG ; Jinu KIM ; Babu J PADANILAM
Kidney Research and Clinical Practice 2019;38(1):6-14
Chronic kidney disease (CKD) is increasing worldwide without an effective therapeutic strategy. Sympathetic nerve activation is implicated in CKD progression, as well as cardiovascular dysfunction. Renal denervation is beneficial for controlling blood pressure (BP) and improving renal function through reduction of sympathetic nerve activity in patients with resistant hypertension and CKD. Sympathetic neurotransmitter norepinephrine (NE) via adrenergic receptor (AR) signaling has been implicated in tissue homeostasis and various disease progressions, including CKD. Increased plasma NE level is a predictor of survival and the incidence of cardiovascular events in patients with end-stage renal disease, as well as future renal injury in subjects with normal BP and renal function. Our recent data demonstrate that NE derived from renal nerves causes renal inflammation and fibrosis progression through alpha-2 adrenergic receptors (α₂-AR) in renal fibrosis models independent of BP. Sympathetic nerve activation-associated molecular mechanisms and signals seem to be critical for the development and progression of CKD, but the exact role of sympathetic nerve activation in CKD progression remains undefined. This review explores the current knowledge of NE-α₂-AR signaling in renal diseases and offers prospective views on developing therapeutic strategies targeting NE-AR signaling in CKD progression.
Blood Pressure
;
Denervation
;
Disease Progression
;
Fibrosis
;
Homeostasis
;
Humans
;
Hypertension
;
Incidence
;
Inflammation
;
Kidney Failure, Chronic
;
Neurotransmitter Agents
;
Norepinephrine
;
Plasma
;
Prospective Studies
;
Receptors, Adrenergic
;
Receptors, Adrenergic, alpha-2
;
Renal Insufficiency, Chronic
;
Reperfusion Injury
4.Neuroimmune interactions and kidney disease
Sho HASEGAWA ; Tsuyoshi INOUE ; Reiko INAGI
Kidney Research and Clinical Practice 2019;38(3):282-294
The autonomic nervous system plays critical roles in maintaining homeostasis in humans, directly regulating inflammation by altering the activity of the immune system. The cholinergic anti-inflammatory pathway is a well-studied neuroimmune interaction involving the vagus nerve. CD4-positive T cells expressing β2 adrenergic receptors and macrophages expressing the alpha 7 subunit of the nicotinic acetylcholine receptor in the spleen receive neurotransmitters such as norepinephrine and acetylcholine and are key mediators of the cholinergic anti-inflammatory pathway. Recent studies have demonstrated that vagus nerve stimulation, ultrasound, and restraint stress elicit protective effects against renal ischemia-reperfusion injury. These protective effects are induced primarily via activation of the cholinergic anti-inflammatory pathway. In addition to these immunological roles, nervous systems are directly related to homeostasis of renal physiology. Whole-kidney three-dimensional visualization using the tissue clearing technique CUBIC (clear, unobstructed brain/body imaging cocktails and computational analysis) has illustrated that renal sympathetic nerves are primarily distributed around arteries in the kidneys and denervated after ischemia-reperfusion injury. In contrast, artificial renal sympathetic denervation has a protective effect against kidney disease progression in murine models. Further studies are needed to elucidate how neural networks are involved in progression of kidney disease.
Acetylcholine
;
Arteries
;
Autonomic Nervous System
;
Cholinergic Neurons
;
Homeostasis
;
Humans
;
Immune System
;
Inflammation
;
Kidney Diseases
;
Kidney
;
Macrophages
;
Nervous System
;
Neurotransmitter Agents
;
Norepinephrine
;
Optogenetics
;
Physiology
;
Receptors, Adrenergic
;
Receptors, Nicotinic
;
Reperfusion Injury
;
Spleen
;
Sympathectomy
;
Sympathetic Nervous System
;
T-Lymphocytes
;
Ultrasonography
;
Vagus Nerve
;
Vagus Nerve Stimulation
6.Intervention measures for maintenance of clinical control in the remission stage of childhood asthma.
Xue ZHANG ; Jia-Hua PAN ; Hao-Quan ZHOU
Chinese Journal of Contemporary Pediatrics 2019;21(6):499-504
OBJECTIVE:
To explore the intervention measures to maintain clinical control in children with asthma in the remission stage when concomitant with acute upper respiratory infection (AURI).
METHODS:
A total of 100 asthmatic children who had achieved clinical control were randomly divided into observation group and control group. The two groups were both treated with a combination of inhaled corticosteroids and long-acting β2 receptor agonist (ICS/LABA) at the lowest dose every night. Conventional therapies were used for the two groups when suffering from AURI. In addition to conventional therapies, the observation group was given early short-term upgrade therapy, i.e., on the basis of maintenance therapy, the same amount of ICS/LABA complex preparation was inhaled every morning, which lasted for 7-10 days. Both groups were treated following asthma guidelines according to the severity of the disease at the time of acute attacks. The control rate of asthma, severity of acute attacks, changes in pulmonary function indices, and occurrence of adverse events were evaluated after 3, 6, 9, and 12 months of treatment.
RESULTS:
At each time point of follow-up, the rate of asthma control in the observation group was significantly higher than that in the control group (90% vs 80%; P<0.05). The severity of acute attacks in the observation group was significantly lower than that in the control group at all follow-up time points (P<0.05). Compared with the control group, the observation group had significantly improved pulmonary function indices of large and small airways (P<0.05) and significantly reduced mean amount of inhaled glucocorticoids and impact on family life (P<0.01).
CONCLUSIONS
Early short-term upgrade therapy for children with asthma in the remission stage when concomitant with AURI can prevent acute attacks of asthma, raise the rate of asthma control and improve pulmonary function.
Administration, Inhalation
;
Adrenal Cortex Hormones
;
Adrenergic beta-Agonists
;
Anti-Asthmatic Agents
;
Asthma
;
Child
;
Drug Therapy, Combination
;
Humans
7.Pharmacogenetic Correlates of Antipsychotic-Induced Weight Gain in the Chinese Population.
Chao LUO ; Junyan LIU ; Xu WANG ; Xiaoyuan MAO ; Honghao ZHOU ; Zhaoqian LIU
Neuroscience Bulletin 2019;35(3):561-580
Antipsychotic-induced weight gain (AIWG) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. We aimed to review the progress of pharmacogenetic studies on AIWG in the Chinese population to compare the results for Chinese with other ethnic populations, identify the limitations and problems of current studies, and provide future research directions in China. Both English and Chinese electronic databases were searched to identify eligible studies. We determined that > 25 single-nucleotide polymorphisms in 19 genes have been investigated in association with AIWG in Chinese patients over the past few decades. HTR2C rs3813929 is the most frequently studied single-nucleotide polymorphism, and it seems to be the most strongly associated with AIWG in the Chinese population. However, many genes that have been reported to be associated with AIWG in other ethnic populations have not been included in Chinese studies. To explain the pharmacogenetic reasons for AIWG in the Chinese population, genome-wide association studies and multiple-center, standard, unified, and large samples are needed.
Antipsychotic Agents
;
adverse effects
;
Asian Continental Ancestry Group
;
genetics
;
China
;
Genome-Wide Association Study
;
Genotype
;
Humans
;
Lipid Metabolism
;
genetics
;
Neurosecretory Systems
;
drug effects
;
Pharmacogenomic Testing
;
Polymorphism, Single Nucleotide
;
Receptors, Adrenergic
;
genetics
;
Receptors, Dopamine
;
genetics
;
Receptors, Histamine
;
genetics
;
Receptors, Serotonin
;
genetics
;
Weight Gain
;
drug effects
;
genetics
8.Electroacupuncture Alleviates Motor Symptoms and Up-Regulates Vesicular Glutamatergic Transporter 1 Expression in the Subthalamic Nucleus in a Unilateral 6-Hydroxydopamine-Lesioned Hemi-Parkinsonian Rat Model.
Yanyan WANG ; Yong WANG ; Junhua LIU ; Xiaomin WANG
Neuroscience Bulletin 2018;34(3):476-484
Previous studies have shown that electroacupuncture (EA) promotes recovery of motor function in Parkinson's disease (PD). However the mechanisms are not completely understood. Clinically, the subthalamic nucleus (STN) is a critical target for deep brain stimulation treatment of PD, and vesicular glutamate transporter 1 (VGluT1) plays an important role in the modulation of glutamate in the STN derived from the cortex. In this study, a 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD was treated with 100 Hz EA for 4 weeks. Immunohistochemical analysis of tyrosine hydroxylase (TH) showed that EA treatment had no effect on TH expression in the ipsilateral striatum or substantia nigra pars compacta, though it alleviated several of the parkinsonian motor symptoms. Compared with the hemi-parkinsonian rats without EA treatment, the 100 Hz EA treatment significantly decreased apomorphine-induced rotation and increased the latency in the Rotarod test. Notably, the EA treatment reversed the 6-OHDA-induced down-regulation of VGluT1 in the STN. The results demonstrated that EA alleviated motor symptoms and up-regulated VGluT1 in the ipsilateral STN of hemi-parkinsonian rats, suggesting that up-regulation of VGluT1 in the STN may be related to the effects of EA on parkinsonian motor symptoms via restoration of function in the cortico-STN pathway.
Adrenergic Agents
;
toxicity
;
Animals
;
Apomorphine
;
pharmacology
;
Disease Models, Animal
;
Dopamine Agonists
;
pharmacology
;
Electroacupuncture
;
methods
;
Functional Laterality
;
drug effects
;
Male
;
Medial Forebrain Bundle
;
injuries
;
Motor Activity
;
drug effects
;
physiology
;
Neurons
;
drug effects
;
metabolism
;
Oxidopamine
;
toxicity
;
Parkinson Disease, Secondary
;
chemically induced
;
physiopathology
;
therapy
;
Rats
;
Rats, Sprague-Dawley
;
Subthalamic Nucleus
;
drug effects
;
metabolism
;
pathology
;
Tyrosine 3-Monooxygenase
;
metabolism
;
Up-Regulation
;
drug effects
;
physiology
;
Vesicular Glutamate Transport Protein 1
;
metabolism
9.Antiarrhythmic drug usage and prostate cancer: a population-based cohort study.
Li-Ting KAO ; Chung-Chien HUANG ; Herng-Ching LIN ; Chao-Yuan HUANG
Asian Journal of Andrology 2018;20(1):37-42
Even though the relationship between antiarrhythmic drug usage and subsequent prostate cancer (PCa) risk has recently been highlighted, relevant findings in the previous literature are still inconsistent. In addition, very few studies have attempted to investigate the association between sodium channel blockers or potassium channel blockers for arrhythmia and the subsequent PCa risk. Therefore, this cohort study aimed to find the relationship between antiarrhythmic drug usage and the subsequent PCa risk using a population-based dataset. The data used in this study were derived from the Longitudinal Health Insurance Database 2005, Taiwan, China. We respectively identified 9988 sodium channel blocker users, 3663 potassium channel blocker users, 65 966 beta-blocker users, 23 366 calcium channel blockers users, and 7031 digoxin users as the study cohorts. The matched comparison cohorts (one comparison subject for each antiarrhythmic drug user) were selected from the same dataset. Each patient was tracked for a 5-year period to define those who were subsequently diagnosed with PCa. After adjusting for sociodemographic characteristics, comorbidities, and age, Cox proportional hazard regressions found that the hazard ratio (HR) of subsequent PCa for sodium channel blocker users was 1.12 (95% confidence interval [CI]: 0.84-1.50), for potassium channel blocker users was 0.89 (95% CI: 0.59-1.34), for beta-blocker users was 1.08 (95% CI: 0.96-1.22), for calcium channel blocker users was 1.14 (95% CI: 0.95-1.36), and for digoxin users was 0.89 (95% CI: 0.67-1.18), compared to their matched nonusers. We concluded that there were no statistical associations between different types of antiarrhythmic drug usage and subsequent PCa risk.
Adrenergic beta-Antagonists/adverse effects*
;
Adult
;
Age Factors
;
Aged
;
Anti-Arrhythmia Agents/adverse effects*
;
Calcium Channel Blockers/adverse effects*
;
Cohort Studies
;
Comorbidity
;
Databases, Factual
;
Digoxin/adverse effects*
;
Humans
;
Incidence
;
Male
;
Middle Aged
;
Potassium Channel Blockers/adverse effects*
;
Prostatic Neoplasms/epidemiology*
;
Retrospective Studies
;
Socioeconomic Factors
;
Sodium Channel Blockers/adverse effects*
;
Taiwan/epidemiology*
10.Three Gaseous Neurotransmitters, Nitric oxide, Carbon Monoxide, and Hydrogen Sulfide, Are Involved in the Neurogenic Relaxation Responses of the Porcine Internal Anal Sphincter.
Oladayo FOLASIRE ; Kylie A MILLS ; Donna J SELLERS ; Russ CHESS-WILLIAMS
Journal of Neurogastroenterology and Motility 2016;22(1):141-148
BACKGROUND/AIMS: The internal anal sphincter (IAS) plays an important role in maintaining continence and a number of neurotransmitters are known to regulate IAS tone. The aim of this study was to determine the relative importance of the neurotransmitters involved in the relaxant and contractile responses of the porcine IAS. METHODS: Responses of isolated strips of IAS to electrical field stimulation (EFS) were obtained in the absence and presence of inhibitors of neurotransmitter systems. RESULTS: Contractile responses of the sphincter to EFS were unaffected by the muscarinic receptor antagonist, atropine (1 muM), but were almost completely abolished by the adrenergic neuron blocker guanethidine (10 muM). Contractile responses were also reduced (by 45% at 5 Hz, P < 0.01) following desensitisation of purinergic receptors with alpha,beta-methylene-ATP (10 muM). In the presence of guanethidine, atropine, and alpha,beta-methylene-ATP, the remaining relaxatory responses to EFS were examined. These responses were not altered by the cyclooxygenase inhibitor, indomethacin (5 muM), the vasoactive intestinal polypeptide receptor antagonist, [D-p-Cl-Phe6,Leu17]-vasoactive intestinal peptide (PheLeu-VIP; 100 nM), or the purinoceptor antagonists, 8-phenyltheophyline (P1 receptors) or suramin (P2 receptors). However, relaxation responses were reduced by Nomega-nitro-L-arginine (L-NNA; 100 muM), an inhibitor of nitric oxide synthesis (40-50% reduction), zinc protoprophyrin IX (10 muM), an inhibitor of carbon monoxide synthesis (20-40% reduction), and also propargylglycine (30 muM) and aminooxyacetic acid (30 muM), inhibitors of hydrogen sulphide synthesis (15-20% reduction). CONCLUSIONS: Stimulation of IAS efferent nerves releases excitatory and inhibitory neurotransmitters: noradrenaline is the predominant contractile transmitter with a smaller component from ATP, whilst 3 gases mediate relaxation responses to EFS, with the combined contributions being nitric oxide > carbon monoxide > hydrogen sulfide.
Adenosine Triphosphate
;
Adrenergic Neurons
;
Aminooxyacetic Acid
;
Anal Canal*
;
Atropine
;
Autonomic Pathways
;
Carbon Monoxide*
;
Carbon*
;
Gases
;
Guanethidine
;
Hydrogen Sulfide*
;
Hydrogen*
;
Indomethacin
;
Neurotransmitter Agents*
;
Nitric Oxide*
;
Norepinephrine
;
Prostaglandin-Endoperoxide Synthases
;
Purinergic Antagonists
;
Receptors, Muscarinic
;
Receptors, Purinergic
;
Relaxation*
;
Suramin
;
Vasoactive Intestinal Peptide
;
Zinc

Result Analysis
Print
Save
E-mail